Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2107 - P53 and ERCC1 gene polymorphisms can predict the recurence risk of breast cancer


10 Oct 2016


Poster display


Tulay Kus


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


T. Kus, G. Aktas, M.E. Kalender, A. Sevinc, C. Camci

Author affiliations

  • Medical Oncology, University of Gaziantep, Kilis way Oncology Hospital, 27100 - Gaziantep/TR


Abstract 2107


Genetic variations, molecular and histopathological features, age and stage predict the recurrence risk of breast cancer patients. Gene polymorphisms encoding the enzymes involved in transport and metabolism of drugs, DNA repair or drug pharmacodynamics may predict the treatment response or chemotherapy resistence. In this context, we aimed to investigate the association of single nucleotide polymoprhisms in NQO1, CYP3A4, ERCC1, ERCC2, FGFR4, TP53, ERBB2, ABCB1 and 5-years reccurent rate.


Operated breast cancer patients followed in Gaziantep University Oncology Hospital between June 2004 and June 2011 were analyzed retrospectively. Clinicopathologic variables and administered treatment schemes were noted. Blood samples were taken and genomic DNA was extracted. ' Genotyping the Fluidigm Digital Array' was performed and 'genomic DNA a 96.96 dynamic array on the BioMark HD system' was used for evaluation. Relations of these parameters with 5-year recurrence risk were analyzed with univariate and multivariate regression models.


286 patients were included in this study. According to tumor size, recurrence rates of T1/T2/T3 and T4 patients were 17.1%/17.2%/34.5% and 18.2% respectively (p = 0.045). According to lymph node status, recurrence rates of N0/N1/N2 and N3 patients were 12%/13.4%/32.6% and 51.4% respectively (p 


ERCC1 and p53 genes can predict the 5-year recurrence risk of lymph node positive breast cancer patients.

Clinical trial identification

Legal entity responsible for the study

Tulay Kus




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings